---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-024065"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T13:39:02.098247+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland reports ifetroban well-tolerated with positive trend in DMD trial; no stat-sig

## Summary
- Interim analysis from 25 patients after 6 months; both ifetroban doses well-tolerated.
- Positive trend in leg muscle strength but no statistically significant differences at this early point.
- Phase II trial evaluating ifetroban for DMD cardiomyopathy; FDA awarded $1M orphan grant.
- Company plans to complete studies, analyze data, then decide development path for ifetroban registration.

## SEC filing metadata
- accession: 0001628280-23-024065
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023024065/0001628280-23-024065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023024065/cpix-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-024065
- JSON: https://secwatch.observer/filing/0001628280-23-024065.json
- Plain text: https://secwatch.observer/filing/0001628280-23-024065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.